{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:34:56Z","timestamp":1792427696477,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41581-021-00424-4","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T11:06:18Z","timestamp":1620212778000},"page":"543-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5390-8002","authenticated-orcid":false,"given":"Fadi","family":"Fakhouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"424_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"217","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri, F., Zuber, J., Fremeaux-Bacchi, V. & Loirat, C. Haemolytic uraemic syndrome. Lancet 217, 681\u2013696 (2017).","journal-title":"Lancet"},{"key":"424_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/ndt\/14.5.1229","volume":"14","author":"P Warwicker","year":"1999","unstructured":"Warwicker, P. et al. Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol. Dial. Transpl. 14, 1229\u20131233 (1999).","journal-title":"Nephrol. Dial. Transpl."},{"key":"424_CR3","doi-asserted-by":"publisher","first-page":"12966","DOI":"10.1073\/pnas.2135497100","volume":"100","author":"A Richards","year":"2003","unstructured":"Richards, A. et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl Acad. Sci. USA 100, 12966\u201312971 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"424_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","volume":"362","author":"M Noris","year":"2003","unstructured":"Noris, M. et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362, 1542\u20131547 (2003).","journal-title":"Lancet"},{"key":"424_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/jmg.2005.030783","volume":"42","author":"V Fremeaux-Bacchi","year":"2005","unstructured":"Fremeaux-Bacchi, V. et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J. Med. Genet. 42, 852\u2013856 (2005).","journal-title":"J. Med. Genet."},{"key":"424_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.019083","volume":"41","author":"V Fremeaux-Bacchi","year":"2004","unstructured":"Fremeaux-Bacchi, V. et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 41, e84 (2004).","journal-title":"J. Med. Genet."},{"key":"424_CR7","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","volume":"112","author":"V Fremeaux-Bacchi","year":"2008","unstructured":"Fremeaux-Bacchi, V. et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112, 4948\u20134952 (2008).","journal-title":"Blood"},{"key":"424_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1073\/pnas.0603420103","volume":"104","author":"E Goicoechea de Jorge","year":"2007","unstructured":"Goicoechea de Jorge, E. et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl Acad. Sci. USA 104, 240\u2013245 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"424_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"2016","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri, F. et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am. J. Kidney Dis. 2016, 84\u201393 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"424_CR10","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169\u20132181 (2013).","journal-title":"N. Engl. J. Med."},{"key":"424_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1681\/ASN.2013050453","volume":"25","author":"F Bu","year":"2014","unstructured":"Bu, F. et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 25, 55\u201364 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi, V. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8, 554\u2013562 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"424_CR13","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris, M. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5, 1844\u20131859 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"424_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1681\/ASN.2015040385","volume":"27","author":"F Bu","year":"2016","unstructured":"Bu, F. et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J. Am. Soc. Nephrol. 27, 1245\u20131253 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR15","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","volume":"200","author":"AJ Osborne","year":"2018","unstructured":"Osborne, A. J. et al. Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. J. Immunol. 200, 2464\u20132478 (2018).","journal-title":"J. Immunol."},{"key":"424_CR16","first-page":"262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system Part I \u2014 molecular mechanisms of activation and regulation. Front. Immunol. 6, 262 (2015).","journal-title":"Front. Immunol."},{"key":"424_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2215\/CJN.05830518","volume":"14","author":"V Fremeaux-Bacchi","year":"2019","unstructured":"Fremeaux-Bacchi, V. et al. Complement gene variants and shiga toxin-producing escherichia coli-associated hemolytic uremic syndrome: retrospective genetic and clinical study. Clin. J. Am. Soc. Nephrol. 14, 364\u2013377 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"424_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3324\/haematol.2019.216903","volume":"104","author":"K El Karoui","year":"2019","unstructured":"El Karoui, K. et al. Impact of hypertensive emergency and complement rare variants on presentation and outcome of atypical hemolytic uremic syndrome. Haematologica 104, 12 (2019).","journal-title":"Haematologica"},{"key":"424_CR19","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1681\/ASN.2018070759","volume":"29","author":"F Bu","year":"2018","unstructured":"Bu, F. et al. Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 29, 2809\u20132819 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer, F. et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 94, 408\u2013418 (2018).","journal-title":"Kidney Int."},{"key":"424_CR21","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","volume":"8","author":"M Le Quintrec","year":"2008","unstructured":"Le Quintrec, M. et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am. J. Transpl. 8, 1694\u20131701 (2008).","journal-title":"Am. J. Transpl."},{"key":"424_CR22","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","volume":"95","author":"A Le Clech","year":"2019","unstructured":"Le Clech, A. et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int. 95, 1443\u20131452 (2019).","journal-title":"Kidney Int."},{"key":"424_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","volume":"127","author":"S Jodele","year":"2016","unstructured":"Jodele, S. et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 127, 989\u2013996 (2016).","journal-title":"Blood"},{"key":"424_CR24","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.bbmt.2017.05.013","volume":"23","author":"G Ardissino","year":"2017","unstructured":"Ardissino, G. et al. Acquired complement regulatory gene mutations and hematopoietic stem cell transplant-related thrombotic microangiopathy. Biol. Blood Marrow Transpl. 23, 1580\u20131582 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"424_CR25","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1055\/s-0040-1702225","volume":"120","author":"E Gavriilaki","year":"2020","unstructured":"Gavriilaki, E. et al. Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy. Thromb. Haemost. 120, 638\u2013646 (2020).","journal-title":"Thromb. Haemost."},{"key":"424_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"Auton, A. et al. A global reference for human genetic variation. Nature. 526, 68\u201374 (2015).","journal-title":"Nature."},{"key":"424_CR27","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2215\/CJN.00280117","volume":"12","author":"A Bruel","year":"2017","unstructured":"Bruel, A. et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin. J. Am. Soc. Nephrol. 12, 1237\u20131247 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"424_CR28","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1681\/ASN.2016090995","volume":"29","author":"M Gaggl","year":"2018","unstructured":"Gaggl, M. et al. Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 29, 1020\u20131029 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","volume":"93","author":"A Huerta","year":"2018","unstructured":"Huerta, A. et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 93, 450\u2013459 (2018).","journal-title":"Kidney Int."},{"key":"424_CR30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","volume":"96","author":"T Cavero","year":"2019","unstructured":"Cavero, T. et al. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney Int. 96, 995\u20131004 (2019).","journal-title":"Kidney Int."},{"key":"424_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99128","volume":"3","author":"AJ Vaught","year":"2018","unstructured":"Vaught, A. J. et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 3, e99128 (2018).","journal-title":"JCI Insight"},{"key":"424_CR32","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","volume":"112","author":"F Fakhouri","year":"2008","unstructured":"Fakhouri, F. et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 112, 4542\u20134545 (2008).","journal-title":"Blood"},{"key":"424_CR33","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3109\/14767058.2012.694923","volume":"25","author":"F Crovetto","year":"2012","unstructured":"Crovetto, F. et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J. Matern. Fetal Neonatal Med. 25, 2322\u20132325 (2012).","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"424_CR34","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1182\/blood.2020006931","volume":"136","author":"E Arjona","year":"2020","unstructured":"Arjona, E., Huerta, A., Goicoechea de Jorge, E. & Rodriguez de Cordoba, S. Familial risk of developing atypical hemolytic-uremic syndrome. Blood. 136, 1558\u20131561 (2020).","journal-title":"Blood."},{"key":"424_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","volume":"45","author":"M Lemaire","year":"2013","unstructured":"Lemaire, M. et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 45, 531\u2013536 (2013).","journal-title":"Nat. Genet."},{"key":"424_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"424_CR37","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.kint.2017.07.015","volume":"93","author":"HM Merinero","year":"2017","unstructured":"Merinero, H. M., Garcia, S. P., Garcia-Fernandez, J., Arjona, E., Tortajada, A. & Rodriguez de Cordoba, S. Complete functional characterization of disease-associated genetic variants in the complement factor H gene. Kidney Int. 93, 470\u2013481 (2017).","journal-title":"Kidney Int."},{"key":"424_CR38","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1681\/ASN.2013070796","volume":"25","author":"MC Marinozzi","year":"2014","unstructured":"Marinozzi, M. C. et al. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J. Am. Soc. Nephrol. 25, 2053\u20132065 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR39","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/ng.2741","volume":"45","author":"JM Seddon","year":"2013","unstructured":"Seddon, J. M. et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat. Genet. 45, 1366\u20131370 (2013).","journal-title":"Nat. Genet."},{"key":"424_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"C Genomes Project","year":"2015","unstructured":"Genomes Project, C. et al. A global reference for human genetic variation. Nature 526, 68\u201374 (2015).","journal-title":"Nature"},{"key":"424_CR41","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","volume":"119","author":"LT Roumenina","year":"2012","unstructured":"Roumenina, L. T. et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119, 4182\u20134191 (2012).","journal-title":"Blood"},{"key":"424_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","volume":"376","author":"DP Gale","year":"2010","unstructured":"Gale, D. P. et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376, 794\u2013801 (2010).","journal-title":"Lancet"},{"key":"424_CR43","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris, M. et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124, 1715\u20131726 (2014).","journal-title":"Blood"},{"key":"424_CR44","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2215\/CJN.05830519","volume":"14","author":"M Palomo","year":"2019","unstructured":"Palomo, M. et al. Complement activation and thrombotic microangiopathies. Clin. J. Am. Soc. Nephrol. 14, 1719\u20131732 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"424_CR45","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1681\/ASN.2018020184","volume":"29","author":"S Timmermans","year":"2018","unstructured":"Timmermans, S. et al. C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension. J. Am. Soc. Nephrol. 29, 2234\u20132243 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","volume":"74","author":"M Galbusera","year":"2019","unstructured":"Galbusera, M. et al. An Ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome. Am. J. Kidney Dis. 74, 56\u201372 (2019).","journal-title":"Am. J. Kidney Dis."},{"key":"424_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","volume":"27","author":"J Zuber","year":"2013","unstructured":"Zuber, J. et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transpl. Rev. 27, 117\u2013125 (2013).","journal-title":"Transpl. Rev."},{"key":"424_CR48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","volume":"66","author":"G Ardissino","year":"2015","unstructured":"Ardissino, G. et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am. J. Kidney Dis. 66, 172\u2013173 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"424_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri, F. et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin. J. Am. Soc. Nephrol. 12, 50\u201359 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"424_CR50","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1053\/j.ajkd.2014.04.039","volume":"65","author":"JF Wetzels","year":"2015","unstructured":"Wetzels, J. F. & van de Kar, N. C. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome. Am. J. Kidney Dis. 65, 342 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"424_CR51","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1681\/ASN.2019040331","volume":"30","author":"J Zuber","year":"2019","unstructured":"Zuber, J. et al. Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 30, 2449\u20132463 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009280","author":"F Fakhouri","year":"2020","unstructured":"Fakhouri, F. et al. Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study. Blood https:\/\/doi.org\/10.1182\/blood.2020009280 (2020).","journal-title":"Blood"},{"key":"424_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa0810739","volume":"361","author":"M Delvaeye","year":"2009","unstructured":"Delvaeye, M. et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 345\u2013357 (2009).","journal-title":"N. Engl. J. Med."},{"key":"424_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060352","volume":"8","author":"LV Holmes","year":"2013","unstructured":"Holmes, L. V. et al. Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32. PLoS One 8, e60352 (2013).","journal-title":"PLoS One"},{"key":"424_CR55","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey, M. A. et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 21, 2180\u20132187 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR56","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","volume":"10","author":"M Puraswani","year":"2019","unstructured":"Puraswani, M. et al. Clinical and immunological profile of anti-factor h antibody associated atypical hemolytic uremic syndrome: a nationwide database. Front. Immunol. 10, 1282 (2019).","journal-title":"Front. Immunol."},{"key":"424_CR57","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1681\/ASN.2015101189","volume":"28","author":"RC Challis","year":"2017","unstructured":"Challis, R. C. et al. Thrombotic microangiopathy in inverted formin 2-mediated renal disease. J. Am. Soc. Nephrol. 28, 1084\u20131091 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR58","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/j.molimm.2009.04.012","volume":"46","author":"AL Stahl","year":"2009","unstructured":"Stahl, A. L. et al. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome. Mol. Immunol. 46, 2236\u20132243 (2009).","journal-title":"Mol. Immunol."},{"key":"424_CR59","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1681\/ASN.2017010031","volume":"28","author":"K Azukaitis","year":"2017","unstructured":"Azukaitis, K. et al. The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase epsilon. J. Am. Soc. Nephrol. 28, 3066\u20133075 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR60","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","volume":"125","author":"S Bruneau","year":"2015","unstructured":"Bruneau, S. et al. Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation. Blood 125, 1038\u20131046 (2015).","journal-title":"Blood"},{"key":"424_CR61","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(15)00076-8","volume":"386","author":"S Grange","year":"2015","unstructured":"Grange, S. et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet 386, 1011\u20131012 (2015).","journal-title":"Lancet"},{"key":"424_CR62","first-page":"1421","volume":"93","author":"C Canigral","year":"2013","unstructured":"Canigral, C. et al. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann. Hematol. 93, 1421\u20131422 (2013).","journal-title":"Ann. Hematol."},{"key":"424_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nep.12935","volume":"22","author":"J Chua","year":"2017","unstructured":"Chua, J., Paizis, K., He, S. Z. & Mount, P. Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab. Nephrology 22, 18\u201322 (2017).","journal-title":"Nephrology"},{"key":"424_CR64","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40620-015-0173-5","volume":"28","author":"E De Sousa Amorim","year":"2015","unstructured":"De Sousa Amorim, E., Blasco, M., Quintana, L., Sole, M., de Cordoba, S. R. & Campistol, J. M. Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J. Nephrol. 28, 641\u2013645 (2015).","journal-title":"J. Nephrol."},{"key":"424_CR65","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/ckj\/sfs185","volume":"6","author":"Y Delmas","year":"2013","unstructured":"Delmas, Y., Bordes, C., Loirat, C., Fremeaux-Bacchi, V. & Combe, C. Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin. Kidney J. 6, 243\u2013244 (2013).","journal-title":"Clin. Kidney J."},{"key":"424_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-8-307","volume":"8","author":"A Kourouklaris","year":"2014","unstructured":"Kourouklaris, A. et al. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J. Med. Case Rep. 8, 307 (2014).","journal-title":"J. Med. Case Rep."},{"key":"424_CR67","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7326\/0003-4819-159-1-201307020-00023","volume":"159","author":"S Zschiedrich","year":"2013","unstructured":"Zschiedrich, S., Prager, E. P. & Kuehn, E. W. Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab. Ann. Intern. Med. 159, 76 (2013).","journal-title":"Ann. Intern. Med."},{"key":"424_CR68","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","volume":"14","author":"G Bayer","year":"2019","unstructured":"Bayer, G. et al. Etiology and outcomes of thrombotic microangiopathies. Clin. J. Am. Soc. Nephrol. 14, 557\u2013566 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"424_CR69","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.ajkd.2015.11.022","volume":"68","author":"M Frimat","year":"2016","unstructured":"Frimat, M. et al. Renal cortical necrosis in postpartum hemorrhage: a case series. Am J Kidney Dis. 68, 50\u201357 (2016).","journal-title":"Am J Kidney Dis."},{"key":"424_CR70","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3109\/00016349609065729","volume":"75","author":"M Haeger","year":"1996","unstructured":"Haeger, M. et al. Increased release of tumor necrosis factor-alpha and interleukin-6 in women with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Acta Obstet. Gynecol. Scand. 75, 695\u2013701 (1996).","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"424_CR71","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","volume":"44","author":"AJ Vaught","year":"2016","unstructured":"Vaught, A. J. et al. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp. Hematol. 44, 390\u2013398 (2016).","journal-title":"Exp. Hematol."},{"key":"424_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001013","volume":"8","author":"JE Salmon","year":"2011","unstructured":"Salmon, J. E. et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 8, e1001013 (2011).","journal-title":"PLoS Med."},{"key":"424_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/HYPERTENSIONAHA.115.05484","volume":"66","author":"M Penning","year":"2015","unstructured":"Penning, M. et al. Classical complement pathway activation in the kidneys of women with preeclampsia. Hypertension 66, 117\u2013125 (2015).","journal-title":"Hypertension"},{"key":"424_CR74","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/10641955.2019.1640725","volume":"38","author":"AR Yonekura Collier","year":"2019","unstructured":"Yonekura Collier, A. R. et al. Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia. Hypertens. Pregnancy 38, 193\u2013199 (2019).","journal-title":"Hypertens. Pregnancy"},{"key":"424_CR75","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","volume":"65","author":"F Bu","year":"2015","unstructured":"Bu, F. et al. Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am. J. Kidney Dis. 65, 968\u2013969 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"424_CR76","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","volume":"31","author":"A Servais","year":"2016","unstructured":"Servais, A. et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol. Dial. Transpl. 31, 2122\u20132130 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"424_CR77","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","volume":"373","author":"RJ Kelly","year":"2015","unstructured":"Kelly, R. J. et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 373, 1032\u20131039 (2015).","journal-title":"N. Engl. J. Med."},{"key":"424_CR78","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","volume":"32","author":"T Cavero","year":"2017","unstructured":"Cavero, T. et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol. Dial. Transpl. 32, 466\u2013474 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"424_CR79","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","volume":"63","author":"F Fakhouri","year":"2014","unstructured":"Fakhouri, F. et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am. J. Kidney Dis. 63, 40\u201348 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"424_CR80","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","volume":"91","author":"S Timmermans","year":"2017","unstructured":"Timmermans, S. et al. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int. 91, 1420\u20131425 (2017).","journal-title":"Kidney Int."},{"key":"424_CR81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/ehjcvp\/pvy032","volume":"5","author":"BH van den Born","year":"2019","unstructured":"van den Born, B. H. et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur. Heart J. Cardiovasc. Pharmacother. 5, 37\u201346 (2019).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"424_CR82","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","volume":"75","author":"S Timmermans","year":"2020","unstructured":"Timmermans, S. et al. Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy. Hypertension 75, 422\u2013430 (2020).","journal-title":"Hypertension"},{"key":"424_CR83","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship, T. H. et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 91, 539\u2013551 (2017).","journal-title":"Kidney Int."},{"key":"424_CR84","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","volume":"37","author":"S Rubin","year":"2019","unstructured":"Rubin, S. et al. Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. J. Hypertens. 37, 316\u2013324 (2019).","journal-title":"J. Hypertens."},{"key":"424_CR85","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2010111130","volume":"23","author":"K El Karoui","year":"2012","unstructured":"El Karoui, K. et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J. Am. Soc. Nephrol. 23, 137\u2013148 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"424_CR86","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/ajh.2009.153","volume":"22","author":"DA Lane","year":"2009","unstructured":"Lane, D. A., Lip, G. Y. & Beevers, D. G. Improving survival of malignant hypertension patients over 40 years. Am. J. Hypertens. 22, 1199\u20131204 (2009).","journal-title":"Am. J. Hypertens."},{"key":"424_CR87","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/00004872-199508000-00013","volume":"13","author":"GY Lip","year":"1995","unstructured":"Lip, G. Y., Beevers, M. & Beevers, D. G. Complications and survival of 315 patients with malignant-phase hypertension. J. Hypertens. 13, 915\u2013924 (1995).","journal-title":"J. Hypertens."},{"key":"424_CR88","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/HYPERTENSIONAHA.115.05241","volume":"65","author":"LA Polgreen","year":"2015","unstructured":"Polgreen, L. A., Suneja, M., Tang, F., Carter, B. L. & Polgreen, P. M. Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. Hypertension 65, 1002\u20131007 (2015).","journal-title":"Hypertension"},{"key":"424_CR89","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1097\/01.hjh.0000249710.21146.38","volume":"24","author":"BJ van den Born","year":"2006","unstructured":"van den Born, B. J., Koopmans, R. P., Groeneveld, J. O. & van Montfrans, G. A. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J. Hypertens. 24, 2299\u20132304 (2006).","journal-title":"J. Hypertens."},{"key":"424_CR90","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1097\/HJH.0000000000001446","volume":"35","author":"A Shantsila","year":"2017","unstructured":"Shantsila, A., Shantsila, E., Beevers, D. G. & Lip, G. Y. H. Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry. J. Hypertens. 35, 2310\u20132314 (2017).","journal-title":"J. Hypertens."},{"key":"424_CR91","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/modpathol.2017.154","volume":"31","author":"CP Larsen","year":"2018","unstructured":"Larsen, C. P., Wilson, J. D., Best-Rocha, A., Beggs, M. L. & Hennigar, R. A. Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy. Mod. Pathol. 31, 488\u2013494 (2018).","journal-title":"Mod. Pathol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41581-021-00424-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-021-00424-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-021-00424-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:10:00Z","timestamp":1684620600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-021-00424-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1038\/s41581-021-00424-4","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.F. has received consultancy and\/or speaker honoraria from Roche, Alexion, Apellis, Achillion, Novartis and Alnylam. V.F.-B has received fees from Alexion Pharmaceuticals, Roche, Apellis, Novartis and Baxter for invited lectures and\/or board membership and is the recipient of a research grant from Alexion Pharmaceuticals and Apellis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}